Immunotherapy in Non-Small-Cell Lung Cancer: A Bridge Between Research and Clinical Practice

Passiglia, Francesco; Commendatore, O.; Vitali, Milena; Conca, Raffaele

doi:10.2217/fon-2018-0098

Cited by 8 publications

(5 citation statements)

References 149 publications

(173 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This system can not only be used for extensive PD-L1 detection but can also be combined with other biological detection materials for comprehensive analysis. In addition, PD-L1 expression is regulated by multiple mechanisms [92], including the MAPK and PI3K or Akt pathways, transcription factors HIF1, STAT3, and NFkB, and epigenetic factors [93]. Meanwhile, the changes in PD-L1 before and after treatment should be considered in clinical application.…”

Section: Pd-l1mentioning

confidence: 99%

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects

Tang

Qin

et al. 2022

Cells

View full text Add to dashboard Cite

Non-small cell lung cancer is one of the most common types of malignances worldwide and the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical resection, chemotherapy, radiotherapy, and targeted therapy, with poor therapeutic effectiveness. In recent years, immune checkpoint inhibitors have applied in NSCLC treatment. A large number of experimental studies have shown that immune checkpoint inhibitors are safer and more effective than traditional therapeutic modalities and have allowed for the development of better guidance in the clinical treatment of advanced NSCLC patients. In this review, we describe clinical trials using ICI immunotherapies for NSCLC treatment, the available data on clinical efficacy, and the emerging evidence regarding biomarkers.

show abstract

Section: Pd-l1mentioning

confidence: 99%

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects

Tang

Qin

et al. 2022

Cells

View full text Add to dashboard Cite

show abstract

“…In recent years, the use of anti-immune checkpoint antibodies has represented a new frontier in the care of several solid tumours such as lung, breast, and prostate tumours [75]. Specifically, therapies that target the PD-1/PD-L1 pathway have shown promising and inspiring effects with remarkably durable responses in lung tumours [76–79] and TNBCs [80]. Indeed, numerous Phase I/II clinical trials to test antibodies that target PD-1 or PD-L1 in breast cancer are ongoing [81, 82].…”

Section: From Molecular Pathology To Molecular Imaging and Vice Versamentioning

confidence: 99%

Combining Diagnostic Imaging and Pathology for Improving Diagnosis and Prognosis of Cancer

Schillaci

Scimeca

Toschi

et al. 2019

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

In the era of personalized medicine, the management of oncological patients requires a translational and multidisciplinary approach. During early phases of cancer development, biochemical alterations of cell metabolism occur much before the formation of detectable tumour masses. Current molecular imaging techniques, targeted to the study of molecular kinetics, employ molecular tracers capable of detecting cancer lesions with both high sensitivity and specificity while also providing essential information for both prognosis and therapy. On the contrary, complementary and crucial information is provided by histopathological examination and ancillary techniques such as immunohistochemistry. Thus, the successful collaboration between diagnostic imaging and anatomic pathology can represent a fundamental step in the “tortuous” but decisive path towards personalized medicine.

show abstract

“…Non-small cell lung cancer (NSCLC) is the most common form of lung cancer (LC) (approximately 85% of all LC cases), consisting of three clinical subtypes: adenocarcinoma, squamous cell carcinoma, and large cell cancer [ 1 ]. In recent years, the discovery of some immune checkpoint blockers (ICBs) targeting lung tumors has demonstrated the immunogenic character of NSCLC; these findings have been determined to have survival benefits for patients with NSCLC [ 2 ]. For instance, the survival year was shown to be extended by 1 year in patients with NSCLC who have been treated with nivolumab compared with those treated with traditional platinum-based regimens [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis

et al. 2022

View full text Add to dashboard Cite

Background The pivotal role of long noncoding RNAs (lncRNAs) in cancer immune responses has been well established. This study was conducted with the aim of exploring the molecular mechanism of lncRNA small nucleolar RNA host gene 12 (SNHG12) in immune escape of non-small cell lung cancer (NSCLC). Methods Expression of lncRNA SNHG12, programmed cell death receptor ligand 1 (PD-L1), ubiquitin-specific protease 8 (USP8), and human antigen R (HuR) in NSCLC tissues and cells was measured, and their binding relationship was determined. NSCLC cell proliferation and apoptosis were assessed. Peripheral blood mononuclear cells (PBMCs) were co-cultured with NSCLC cells. The ratio of CD8+ T cells, PBMC proliferation, and inflammatory factors were determined. lncRNA SNHG12 localization was assessed via subcellular fractionation assay. The half-life period of mRNA was determined using actinomycin D. Xenograft tumor models were established to confirm the role of lncRNA SNHG12 in vivo. Results LncRNA SNHG12 was found to be prominently expressed in NSCLC tissues and cells, which was associated with a poor prognosis. Silencing lncRNA SNHG12 resulted in the reduction in proliferation and the promotion of apoptosis of NSCLC cells, while simultaneously increasing PBMC proliferation and the ratio of CD8+ T cells. Mechanically, the binding of lncRNA SNHG12 to HuR improved mRNA stability and expression of PD-L1 and USP8, and USP8-mediated deubiquitination stabilized the protein level of PD-L1. Overexpression of USP8 or PD-L1 weakened the inhibition of silencing lncRNA SNHG12 on the immune escape of NSCLC. Silencing lncRNA SNHG12 restricted tumor growth and upregulated the ratio of CD8+ T cells by decreasing USP8 and PD-L1. Conclusion LncRNA SNHG12 facilitated the immune escape of NSCLC by binding to HuR and increasing PD-L1 and USP8 levels.

show abstract

Immunotherapy in Non-Small-Cell Lung Cancer: A Bridge Between Research and Clinical Practice

Cited by 8 publications

References 149 publications

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects

Combining Diagnostic Imaging and Pathology for Improving Diagnosis and Prognosis of Cancer

Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis

Contact Info

Product

Resources

About